根据中国国家癌症中心发布的数据，2022年全国原发性肝癌发病人数36.77万，位列各种癌症新发病人数第4位（肺、结直肠、甲状腺、肝），发病率位列第5位（肺、女性乳腺、甲状腺、结直肠、肝）；2022年因原发性肝癌死亡人数31.65万^[1,2]，死亡人数和死亡率均位列第2位（肺、肝）。原发性肝癌主要包括肝细胞癌（hepatocellular carcinoma，HCC）、肝内胆管癌（intrahepatic cholangiocarcinoma，ICC）和混合型肝细胞癌-胆管癌（combined hepatocellular-cholangiocarcinoma，cHCC-CCA）3种不同病理学类型，三者在发病机制、生物学行为、病理组织学、治疗方法以及预后等方面差异较大，其中HCC占75%～85%、ICC占10%～15%^[3,4]。本指南中的"肝癌"仅指HCC。

Kidney injury is a common complication after liver transplantation, including acute kidney injury and chronic kidney disease. Kidney injury in liver transplant recipients seriously affects their long-term survival and life quality, and is one of the main causes of death after liver transplantation. In order to standardize and optimize the diagnosis and treatment of kidney injury in liver transplant recipients, Branch of Organ Transplant of Chinese Medical Association and Branch of Organ Transplant Physicians of Chinese Medical Doctor Association organize experts to develop the "Clinical Practice Guidelines for Kidney Injury Management of Liver Transplant Recipients in China (2023 Edition)" to adapt to the rapid development of diagnosis and treatment. The guideline is based on "Chinese expert consensus on management of kidney injury in liver transplant recipients (2017 edition)" and in conjunction with recent evidence-based medicine and clinical practice experience in China. This guideline focuses on the definition, classification, assessment and preoperative, intraoperative and postoperative prevention and treatments of kidney injury in liver transplant recipients. By presenting a series of scientifically standardized recommendations, the guideline is aimed to optimize the management of kidney injury in liver transplant recipients in China.

血管分割与重建是劈离式肝移植的最关键技术之一，为规范劈离式肝移植血管分割与重建的技术流程，优化手术细节，降低相关并发症发生，进而促进我国劈离式肝移植快速发展，由中华医学会外科学分会外科手术学学组、中华医学会外科学分会移植学组、华南劈离式肝移植联盟组织国内领域知名专家，针对供肝血管评估、分割原则、供受体匹配、血管重建等技术细节和方案制定中国专家共识。